Navigation Links
Chimerix Announces Presentation of Final Data from CMX001 Phase 2 Trial in Prophylaxis of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
Date:1/25/2012

RESEARCH TRIANGLE PARK, N.C., Jan. 25, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced that final data from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV), has been accepted for oral presentation at the BMT Tandem Meetings on February 1-5, 2012, in San Diego, California.  CMX001 is a broad spectrum, Lipid-Antiviral-Conjugate completing Phase 2 clinical development for the prevention of CMV in hematopoietic cell transplant (HCT) recipients.  In total, three abstracts related to CMX001 have been accepted for presentation at the 2012 BMT Tandem Meetings, the combined annual meetings of the Center for International Blood and Marrow Transplant Research (CIBMTR) and the American Society of Blood and Marrow Transplantation (ASBMT).

Francisco Marty, MD, Assistant Professor of Medicine at Brigham and Women's Hospital's Division of Infectious Disease and a lead investigator in Chimerix's CMX001 Phase 2 CMV study, will present the data during the "Best Abstracts Plenary Session" at 4:45 pm on Friday, February 3 in the Elizabeth Ballroom at the Manchester Grand Hyatt in San Diego.  The presentation, entitled "CMX001 for Prevention and Control of CMV Infection in CMV-Seropositive Allogeneic Stem Cell Transplant Recipients: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial of Safety, Tolerability and Antiviral Activity," will highlight safety and efficacy results from the Phase 2 trial in 230 hematopoietic cell transplant recipients.  

"Existing therapies for the prophylaxis and treatment of viral infections, including CMV, in the transplant recipient population are limited by their lack of broad spectrum efficacy and major side effects, notably nephrotoxicity and myelosuppression," said Wendy P. Painter, MD, MPH, Chimerix's Chief Medical Officer.  "The prevalence of the disease and the limita
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Chimerix to Present at Upcoming Lazard and Piper Jaffray Healthcare Conferences
2. Chimerix Honored With "2011 Southeast BIO Deal of the Year: Venture Capital Transaction" Award
3. Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting
4. Chimerix to Present at Infocasts 9th Annual Biodefense Vaccines & Therapeutics Conference
5. Chimerix Appoints Timothy W. Trost Senior Vice President, Chief Financial Officer
6. Chimerix to Present at Cowen and Company 31st Annual Health Care Conference
7. Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerixs Lead Antiviral CMX001
8. Chimerix to Present at the Citi 2011 Global Health Care Conference
9. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
(Date:7/11/2014)... Europe is one of the largest ... hence, irrigated land area. The agricultural sector is a ... around 30.0% of the total water use. The scale ... southern region, but far from negligible in most northern ... over 60.0% of the water use in most countries, ...
(Date:7/11/2014)... understand the best available treatment for patients, from a ... costly for taxpayers than the existing clinical trial process, ... Staa, carried out while he was a member of ... now based at The University of Manchester,s Health eResearch ... HTA ) today (Friday 11 July) looked at the ...
(Date:7/11/2014)... Salt Lake City, UT (PRWEB) July 11, 2014 ... hard at work at the Kilimanjaro Kids Community in Tanzania. ... children, 40 goats, 150 chickens, and two cows. HOP Founder, ... and provide education for some of the orphaned children he ... week, the HOP Team visited the children, who have all ...
(Date:7/11/2014)... being prescribed exercise as medicine, according to a ... activity is essential to reducing the risk of ... from QUT,s Institute of Health and Biomedical Innovation, ... physical and mental health, health professionals should be ... Professor Anderson and QUT,s Dr Charlotte Seib co-authored ...
(Date:7/11/2014)... July 11, 2014 Emily Johnson, owner of the ... Her fitness boot camp has held two charity workout ... on Saturday, July 26th, from 7:15 - 8:30 at Col Summers ... first charity boot camp session raised $510 for Medical Teams International. ... non-profit I Have a Dream. On July 26th, Johnson and ...
Breaking Medicine News(10 mins):Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3Health News:Better use of electronic health records makes clinical trials less expensive 2Health News:Human Outreach Project Sees Incredible Progress in the Kilimanjaro Kids Community 2Health News:Exercise is the best medicine: QUT study 2Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 2Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 3
... Council will launch its 2009 June National Safety Month with free enrollment ... , "Alive at ... "First Aid and CPR with AED," basic training ... "Alive at 25 Parent Program" is an engaging, science-based course that educates ...
... is certain: there,s no place like home. Now, a study ... is true for rats. Although inner city rodents appear to ... majority of their lives. , Like any major city, Baltimore ... But scientists from the Johns Hopkins Bloomberg School of Public ...
... staff connect using technology powered by 100 ... solutionsJERICHO, N.Y., May 26 Optimum Lightpath, ... for New York metropolitan area businesses, today ... solution available exclusively through Optimum Lightpath to ...
... the two illnesses , , TUESDAY, May 26 (HealthDay News) ... heart disease has been discovered by German scientists. , ... has been known for years, but a genetic link ... Kiel team found that the two diseases share a ...
... Scheduled for Monday June 1 at 1:00 PM ET ... Calif., May 26 Sunesis Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of new oncology therapeutics, today announced ... 2 clinical trials in frontline acute myeloid leukemia (AML) ...
... dental expert notes importance of regular oral care to protect ... Results from a 2008 Gallup-Healthways poll(1) show that 42 percent ... 12 months, even though the American Dental Association recommends having ... percent of all Americans responded that they did not see ...
Cached Medicine News:Health News:National Safety Council Launches June National Safety Month With Free Training 2Health News:Optimum Lightpath(SM) and GetWellNetwork(R) Transform Hospital Bedside Care with Launch of Interactive Patient Care Service 2Health News:Optimum Lightpath(SM) and GetWellNetwork(R) Transform Hospital Bedside Care with Launch of Interactive Patient Care Service 3Health News:Optimum Lightpath(SM) and GetWellNetwork(R) Transform Hospital Bedside Care with Launch of Interactive Patient Care Service 4Health News:Gum Disease, Heart Disease Share Genetic Link 2Health News:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO 2Health News:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO 3Health News:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO 4Health News:Hispanics Placing Their Oral Health at Risk by Cutting Back on Routine Dental Care 2Health News:Hispanics Placing Their Oral Health at Risk by Cutting Back on Routine Dental Care 3
Anodized aluminum. Durable and lightweight with built-in protection against rust. Security locks ensure against accidental opening. Silicone matting/V-strips and bumper guards hold instruments in pla...
... Storage in bottom of ... accessories, etc. Anodized aluminum. Durable ... against rust. Security locks ensure ... and bumper guards hold instruments ...
Size: 3 x 6 inches. Depth: 1 inch. Sterilizable plastic tray with silicone matting for supporting and protecting instruments....
Size: 6 x 10 inches. Depth: 7 inches. Sterilizable plastic tray with silicone matting for supporting and protecting instruments....
Medicine Products: